INS and type 2 diabetes mellitus: No difference between IGlar and NPH, both in combination with prandial insulin, was observed with respect to the mean reduction of HbA1c (2 RCTs; WMD = 0.02 % [−0.30, 0.35] (0.2 mmol/mol [−3.3; 3.8])) as well as the number of T2DM patients achieving target HbA1c (1 RCT; RB = 1.14 [0.91; 1.44]) [46].